Cytokine release syndrome and allogeneic anti-CD123 chimeric antigen receptor T-cell therapy for acute myeloid leukaemia
Following the success of CAR T-cell therapy in treatment of B-cell malignancies, this approach is being explored across a range of cancers, including acute myeloid leukaemia (AML). However, CAR T-cells and other immunotherapies can cause major toxicity in the form of cytokine release syndrome (CRS). CRS is thought to result from activation of host monocytes/macrophages, but the details of this process are not well characterised. By modelling the behaviour of healthy and malignant monocytic cells during CRS, we aim to identify new methods for prediction, prevention and treatment – both in the context of AML and more broadly.